Medicare part D after 2 years

Am J Manag Care. 2009 Aug;15(8):536-44.

Abstract

Objective: To assess the broad impacts of Medicare Part D and the extent to which prior concerns have been realized.

Methods: We used administrative data to summarize beneficiary enrollment and plan participation in Part D, and compared pharmaceutical use and out-of-pocket spending before and after the introduction of Part D. We characterized the benefit designs of the 10 largest Part D plans in 2006 and compared them with the benefit designs of 7 non-Part D plans often cited as examples of low-cost or comprehensive drug benefits.

Results: By 2008, nearly 90% of seniors had drug coverage at least as generous as the standard Part D benefit. Excluding premiums, annual out-of-pocket spending in the 10 largest Part D plans was comparable to that of other private and public drug benefits, with the most prominent differences attributable to out-of-pocket spending on drugs not covered in the plan. Poorer beneficiaries have gained the most from Part D in terms of increased access to medications and reduced out-of-pocket spending.

Conclusions: Coverage under Part D is comparable to that under non-Part D plans with respect to key features that are likely to be important to Medicare beneficiaries--access to medications and out-of-pocket costs. Nonetheless, concerns remain over drug pricing and gaps in coverage. The government should continue to monitor the competitiveness of the Part D market to ensure it meets the diverse needs of Medicare beneficiaries.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Health Expenditures / statistics & numerical data*
  • Health Expenditures / trends
  • Humans
  • Medicare Part D / economics*
  • Medicare Part D / standards
  • Medicare Part D / statistics & numerical data
  • Pharmaceutical Services / economics*
  • Pharmaceutical Services / statistics & numerical data
  • Prescription Drugs / economics*
  • Prescription Drugs / therapeutic use
  • Program Evaluation
  • United States

Substances

  • Prescription Drugs